Latest Breaking News On - Inselspital bern - Page 7 : comparemela.com

ENDRA Life Sciences Inc.: ENDRA Life Sciences Announces New Clinical Study Partnership with Inselspital University Hospital in Bern, Switzerland ® Ultrasound Device in NAFLD Patients as Commercialization Begins ANN ARBOR, MI / ACCESSWIRE / February 17, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of enhanced ultrasound technologies, today announced that Inselspital University Hospital in Bern, Switzerland is partnering with ENDRA for a clinical study of ENDRA s Thermo Acoustic Enhanced UltraSound (TAEUS ®) device for assessing Non-Alcoholic Fatty Liver Disease (NAFLD). We are very excited that Inselspital Bern, a renowned Swiss clinical and teaching institution, is evaluating TAEUS ® as a non-invasive tool to characterize NAFLD, a condition that impacts more than 1 billion people globally, said ENDRA Life Sciences Chief Commercial Officer Renaud Maloberti. ENDRA is honored to add this leading research institution to our growing list of clinical study pa

Annalisa berzigottiRenaud malobertiDavid wellsKim sutton golodetzInselspital university hospitalCompany contactDrug administrationUniversity hospital of berneUniversity clinic for visceral surgeryUniversity hospital bernDepartment for biomedical researchExchange commissionEuropean unionLife sciencesSecurities exchangeLife sciences inc